Dr. Reddys Laboratories Ltd.

BSE: 500124 | NSE: DRREDDY
Mid Cap | Pharmaceuticals & Drugs
1234.60
-10.90 (-0.88%)
< Home < Back

Dr. Reddy’s launches Ephedrine Sulfate Injection in US market

Date: 30-10-2021

Dr. Reddy’s Laboratories has launched Ephedrine Sulfate Injection USP, 50 mg/mL, a therapeutic equivalent generic version of Akovaz (ephedrine sulfate injection) Injection, 50 mg/mL approved by the U.S. Food and Drug Administration (USFDA).

The Akovaz brand and generic market had U.S. sales of approximately $67.5 million MAT for the most recent twelve months ending in August 2021 according to IQVIA Health. Dr. Reddy’s Ephedrine Sulfate Injection USP, 50 mg/mL is a clear, colorless, sterile solution for intravenous injection and supplied as a 1 mL fill in a 2 mL clear glass single-dose vial with purple flip-off cap. Each mL contains 50 mg of ephedrine sulfate USP, equivalent to 38 mg ephedrine base.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.